Prostate News and Research

RSS

Higher intake of lycopene may lower risk of renal cell carcinoma in postmenopausal women

A higher intake by postmenopausal women of the natural antioxidant lycopene, found in foods like tomatoes, watermelon and papaya, may lower the risk of renal cell carcinoma, a type of kidney cancer.

2 Mar 2015

Endo International’s revenues increase $800 million to 37% in fourth quarter 2014

Endo International plc today reported fourth quarter 2014 revenues of $800 million, an increase of 37 percent compared to fourth quarter 2013 revenues of $585 million, including new product revenue from 2014 strategic M&A transactions.

2 Mar 2015

Study shows only 44% of black males prefer to be investigated for prostate cancer

The incidence of prostate cancer among men of Afro-Caribbean origin is higher than in white men, they are more likely to be diagnosed as emergencies and their mortality rates are higher.

2 Mar 2015

NICE recommends transurethral resection in saline system as the new gold standard for transurethral resection of the prostate

New guidance has been released today by the National Institute for Health and Care Excellence (NICE) recommending Olympus Medical’s transurethral resection in saline (TURis) system for use in surgery to reduce the size of enlarged prostate glands in men. NICE published the guidance in light of the potential it offers NHS hospitals to realise substantial cost savings of £285-£375 per patient whilst also improving patient outcomes.

From Evident Corporation - Life Sciences 27 Feb 2015

Varian reports progress towards making advanced treatments available for cancer patients in Africa

Varian Medical Systems, world leader in radiation therapy, is today reporting progress towards its goal of making advanced treatments systems more available for cancer patients across Africa. The company is presenting to government and healthcare leaders at the 2nd Africa Healthcare Summit.

27 Feb 2015

Study focuses on improving therapeutic outcomes in cancer patients through diet-drug combination

Boosting anti-cancer immunity through diet and novel drug therapies—that's the idea behind a collaborative project involving researchers from the South Dakota State University College of Pharmacy and Sanford Research in Sioux Falls.

27 Feb 2015

Scientists use graphene to target, neutralise cancer stem cells

University of Manchester scientists have used graphene to target and neutralise cancer stem cells while not harming other cells.

25 Feb 2015

AR-V7 status does not affect response to taxane chemotherapy in patients with mCRPC

Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Treatment outcomes were largely similar for the 17 patients with AR-V7-positive prostate cancer and the 20 patients with AR-V7-negative disease included in this analysis.

25 Feb 2015

Study shows that even breast cancers with few androgen receptors benefit from anti-androgen therapy

A University of Colorado Cancer Center study published today in the journal Molecular Cancer Therapeutics shows that only about 1 percent of triple-negative breast cancer cells in a tumor must be "androgen-receptor-positive" to show benefit from anti-androgen therapies.

25 Feb 2015

PCF announces Challenge Awards to support research on new treatment strategies for prostate cancer

The Prostate Cancer Foundation (PCF) announces 3 new Challenge Awards to support discoveries for the treatment of lethal prostate cancer.

25 Feb 2015

Accuray, Lancaster announces commercial availability of InCise MLC for CyberKnife M6 System

Accuray Incorporated and Lancaster General Health announced today that the first commercially available InCise Multileaf Collimator (MLC) for the CyberKnife M6 System has been received by Lancaster.

24 Feb 2015

New NCCN Guidelines for treating Acute Lymphoblastic Leukemia

According to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Acute Lymphoblastic Leukemia (ALL), the treatment approach to ALL is one of the most complex and intensive programs in cancer therapy.

24 Feb 2015

NeoGenomics' revenue increases 36% to $25.0 million in fourth quarter 2014

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the fourth quarter and full year of 2014.

24 Feb 2015

Two widely used targeted therapy drugs not effective in preventing return of kidney cancer

Two widely used targeted therapy drugs— approved by the FDA for use in metastatic kidney cancer —are no more effective than a placebo in preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery, according to new results to be presented by a researcher at the University of Pennsylvania's Abramson Cancer Center during the 2015 Genitourinary Cancers Symposium.

24 Feb 2015

MD Anderson awarded more than $22 million in research grants from CPRIT

The University of Texas MD Anderson Cancer Center has received more than $22 million in research grants this week from the Cancer Prevention and Research Institute of Texas. Approximately half of the funds awarded for Individual Investigator Research Awards went to MD Anderson faculty as well as 40 percent of total IIRA awards that include those for children's and adolescent cancer and early detection and prevention.

21 Feb 2015

Research findings lay groundwork for improving treatment assessment for men with prostate cancer

UCLA researchers have found that radiation therapy is the most common treatment for men with prostate cancer regardless of the aggressiveness of the tumor, risk to the patient and overall patient prognosis. These findings lay the groundwork for improved treatment assessment by physicians and to better inform men fighting the disease.

20 Feb 2015

Scientists identify promising new therapeutic target for prostate cancer

Keck Medicine of the University of Southern California scientists have found a promising new therapeutic target for prostate cancer. The findings offer evidence that a newly discovered member of a family of cell surface proteins called G-protein coupled receptors (GPCRs) promotes prostate cancer cell growth. The protein, GPR158, was found while the researchers were looking for new drug targets for glaucoma.

20 Feb 2015

CTCA presents research on new cancer nutrition therapies at A.S.P.E.N. Clinical Nutrition Week

Several Cancer Treatment Centers of America clinicians presented research from studies evaluating new cancer nutrition techniques and therapies at the American Society for Parenteral and Enteral Nutrition Clinical Nutrition Week held in Long Beach, Calif., February 14-17, 2015. CTCA clinicians led a plenary session and an oral abstract presentation, and presented eight posters to Clinical Nutrition Week attendees.

18 Feb 2015

Researchers say that cancer experience can lead to healthy lifestyle in survivors and family members

After studying cancer survivors and their family caregivers, researchers at Case Western Reserve University conclude that the period between the final cancer treatment and first post-treatment checkup may be an ideal time for the entire household to jumpstart a healthy lifestyle.

18 Feb 2015

Cabazitaxel therapy may be more effective in treating prostate cancer

Prostate cancer is the second leading cause of cancer for men in the United States. Only one class of chemotherapy called taxanes is effective against the disease.

17 Feb 2015

Prostate News and Research

Higher intake of lycopene may lower risk of renal cell carcinoma in postmenopausal women

Endo International’s revenues increase $800 million to 37% in fourth quarter 2014

Study shows only 44% of black males prefer to be investigated for prostate cancer

NICE recommends transurethral resection in saline system as the new gold standard for transurethral resection of the prostate

Varian reports progress towards making advanced treatments available for cancer patients in Africa

Study focuses on improving therapeutic outcomes in cancer patients through diet-drug combination

Scientists use graphene to target, neutralise cancer stem cells

AR-V7 status does not affect response to taxane chemotherapy in patients with mCRPC

Study shows that even breast cancers with few androgen receptors benefit from anti-androgen therapy

PCF announces Challenge Awards to support research on new treatment strategies for prostate cancer

Accuray, Lancaster announces commercial availability of InCise MLC for CyberKnife M6 System

New NCCN Guidelines for treating Acute Lymphoblastic Leukemia

NeoGenomics' revenue increases 36% to $25.0 million in fourth quarter 2014

Two widely used targeted therapy drugs not effective in preventing return of kidney cancer

MD Anderson awarded more than $22 million in research grants from CPRIT

Research findings lay groundwork for improving treatment assessment for men with prostate cancer

Scientists identify promising new therapeutic target for prostate cancer

CTCA presents research on new cancer nutrition therapies at A.S.P.E.N. Clinical Nutrition Week

Researchers say that cancer experience can lead to healthy lifestyle in survivors and family members

Cabazitaxel therapy may be more effective in treating prostate cancer

What to know about prostate cancer eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News